

## Strax Q3 2022 - Steps in the right direction

Management continues to execute according to its action list, having divested two brands plus its licensing business in Q3. It aims to sell its Health & Wellness business in the coming two to four months. Having cut revenues and EBIT by around 7%, we have adjusted our Base Case only marginally from SEK3. 1 to SEK2.9.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

## Attachments

Strax Q3 2022 - Steps in the right direction